Feature|Videos|October 3, 2025
The Secrets of Successful Drug Launches: Cleaning Up Operations
Jason O’Neill, author of 'The Secrets of Successful Drug Launches' and former Dendreon CEO, covers the five stages of the innovation process and how they can be used to improve operations.
Advertisement
Episodes in this series
Advertisement
Related to this article
Merck KGaA, Darmstadt, Germany, agrees to acquire Silence Therapeutics for roughly $1.3 billion, gaining a siRNA asset, divesiran.
Roche licenses Rona Therapeutics’ ALK7-targeting RNAi candidate for obesity, while Pfizer partners with Enodia Therapeutics on Sec61 inhibitor discovery.
As CROs, labs, and other outside partners gain early access to trial and FDA data that sponsor employees have, experts say closing the gap starts with rewriting confidentiality language.
Thomas Appio has been named interim CEO of Bausch + Lomb, a move coinciding with an expected upward revision to the company’s full-year guidance.
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Advertisement
Advertisement
Trending on PharmExec
1
Merck KGaA, Darmstadt, Germany, Acquires Silence Therapeutics for $1.3 Billion
2
Hansoh Pharma Enters $15 Billion Collaboration and License Agreement with Roche
3
Is Participation in MFN Voluntary?
4
The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble
5